bryet, Author at BrYet

BrYet Files IND Application for ML-016, Lead Oncology Therapeutic for Advanced Solid Tumors with Lung and/or Liver Metastases

by bryet | Mar 4, 2026 | Press Releases

HOUSTON (March 4, 2026) — BrYet US, Inc. (“BrYet”) — a biotechnology innovator focused on developing curative therapies for advanced cancers — announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration...

BrYet US, Inc. Expands Patent Portfolio with New U.S. Patent for Targeted Drug Delivery

by bryet | Nov 13, 2025 | Press Releases

Near-term applications include combinations with kinase inhibitors (KIs) that achieve enhanced concentration at target sites and synergistic delivery of multiple KIs to the same location HOUSTON (November 13, 2025) — BrYet US, Inc. — a biotechnology innovator focused...

BrYet US, Inc. Receives Approval to Initiate in Australia a First-in-Human Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement

by bryet | Oct 6, 2025 | Press Releases

HOUSTON and SUNSHINE COAST, Queensland (October 6, 2025) — BrYet US, Inc. (“BrYet”), a biotechnology innovator developing a drug with the potential to be a first-in-class medicine for metastatic disease, today announced that it has received an Australian Human...